CDSCO takes steps to prevent illegal manufacturing, sale and distribution of Oxytocin
An Office Memorandum dated 21st May, 2018, has been issued by the Central Drugs Standard Control Organization (“CDSCO”) on special operations to prevent and detect illegal manufacturing of (API Formulations) and importing Oxytocin into India.
The Office Memorandum reiterates the directions issued by the Ministry of Health and Family Welfare on 27th April, 2018 to regulate and restrict the manufacture, sale and distribution of Oxytocin in the country and prevent its misuse.
The Directions will be effective from July 1st, 2018. It also reiterates the prohibition on import of Oxytocin since 24th April, 2018.
CDSCO has also issued internal directions to conduct special operations to prevent and detect illegal manufacturing, sale and distribution of Oxytocin with the co-operation of police wherever required.